SPECTAcolor update
GI group meeting

St Gallen,
March 14th 2018
• **SPECTAcolor**: 11 participating countries (Belgium, Cyprus, France, Germany, Greece, Italy, Poland, Portugal, Spain, Sweden and Switzerland) and 28 sites open to patient entry; 1070 patients registered and 957 eligible

• **985 samples still available**: primary tumor (632), met (213), normal tissue (90)
AYA in SPECTAcolor

- 150 patients younger than 50 at time of registration is SPECTA
- 96 were analyzed by sequencing at 14MG
- Gene expression was performed on 14 patients (Almac)
- 18 were screened for the STARTRK-2 trial.
957 patients eligible

943 patients MSI testing

593 patients NGS (14MG)

140 patients: Gene expression (done by Almac)
HA staining (done by Halozyme)

Ignyta: 317 samples sent, 1 patient positive